Abiopharma

MAXCYTE, INC. (MXCT)

Symbol	MXCT
Name	MAXCYTE, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Commercial Physical & Biological Resarch
Address	9713 KEY WEST AVENUE,SUITE 400, ROCKVILLE, Maryland, 20850, United States
Telephone	+1 301 - 944-1700
Fax	—
Email	—
Website	https://www.maxcyte.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001287098
Description	MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies. Additional info from NASDAQ: MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.

2026-06-22 20:29

Johnston John Joseph 🟢 acquired 80.0K shares (1 derivative) of MAXCYTE, INC. (MXCT) at $1.13 Transaction Date: Jun 17, 2026 | Filing ID: 003056

2026-06-22 20:28

Hemrajani Rekha 🟢 acquired 80.0K shares (1 derivative) of MAXCYTE, INC. (MXCT) at $1.13 Transaction Date: Jun 17, 2026 | Filing ID: 003055

2026-06-22 20:28

Erck Stanley C 🟢 acquired 80.0K shares (1 derivative) of MAXCYTE, INC. (MXCT) at $1.13 Transaction Date: Jun 17, 2026 | Filing ID: 003054

2026-06-22 20:26

DOUGLAS RICHARD 🟢 acquired 80.0K shares (1 derivative) of MAXCYTE, INC. (MXCT) at $1.13 Transaction Date: Jun 17, 2026 | Filing ID: 003053

2026-06-22 20:25

Collins Cynthia 🟢 acquired 80.0K shares (1 derivative) of MAXCYTE, INC. (MXCT) at $1.13 Transaction Date: Jun 17, 2026 | Filing ID: 003052

2026-06-22 20:25

Brooke William W 🟢 acquired 80.0K shares (1 derivative) of MAXCYTE, INC. (MXCT) at $1.13 Transaction Date: Jun 17, 2026 | Filing ID: 003051

2026-06-22 20:23

Al-Wakeel Yasir B. 🟢 acquired 80.0K shares (1 derivative) of MAXCYTE, INC. (MXCT) at $1.13 Transaction Date: Jun 17, 2026 | Filing ID: 003049

2026-06-17 20:59

(99% Neutral) MAXCYTE, INC. (MXCT) Announces Regulatory Update

2026-06-16 20:21

(99% Neutral) MAXCYTE, INC. (MXCT) Files Form 8-K

2026-06-11 02:25

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT03608618	Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ov…	Phase1	Peritoneal Mesothelioma	Terminated	2018-08-27	2021-08-24	ClinicalTrials.gov

Total clinical trials: 1

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Cyclophosphamide	Other	Phase PHASE1	Peritoneal Mesothelioma	TERMINATED	NCT03608618
MCY-M11	Other	Phase PHASE1	Peritoneal Mesothelioma	TERMINATED	NCT03608618
Cyclophosphamide	DRUG	Phase PHASE1	Peritoneal Mesothelioma	TERMINATED	NCT03608618
MCY-M11	BIOLOGICAL	Phase PHASE1	Peritoneal Mesothelioma	TERMINATED	NCT03608618

Total products: 4